Darden Restaurants arrives at Thursday's earnings print with the options market sending a strikingly different signal than it was just days ago — and with the Street's consensus fractured by a fresh downgrade.
The sharpest shift this week is in options positioning. Put/call sentiment has reversed hard. The PCR fell to 1.00 on June 23, nearly 2.7 standard deviations below its 20-day average of 1.21 — a near-complete unwind of the defensive hedging that dominated the pre-earnings setup described in earlier notes. A week ago, traders were piling into downside protection ahead of the June 25 print. Now the balance has swung decisively toward calls. That z-score of -2.7 is close to the most bullish reading of the past year, against a 52-week PCR range of 0.62 to 1.41. Whether that reflects genuine conviction or short-dated call buying into the event, the options market is no longer flashing caution.
The lending picture remains an afterthought for this name. Availability runs at 700% — roughly seven shares available to borrow for every one already shorted — and cost to borrow has eased 6% over the week to 0.44%, near the low end of its 30-day range. Short interest, at 5.2% of the free float, ticked up fractionally this week after a month of gradual decline. There is no squeeze pressure here, no sign of an aggressive bear build, and no stress in the borrow market. The positioning story is entirely in the options, not the lending pool.
The Street is less unanimous than it appeared. Evercore ISI downgraded DRI to In-Line from Outperform on June 23 — keeping its $230 target but stepping off the accelerator heading into results. That sits in contrast to Guggenheim, which simultaneously raised its target from $230 to $235 while reiterating Buy. The broader analyst consensus remains constructive: 14 buy ratings to 11 holds, with a mean target of $226 against the current price of $210.59. BofA's $276 target, raised earlier this month, is a significant outlier on the high end. EPS momentum factor scores back the bull case — the 30-day reading ranks in the 94th percentile of the universe, and the 90-day at the 79th — but valuation offers no particular cushion, with the stock trading at roughly 17.9x trailing earnings and an EV/EBITDA of 13.7x.
Earnings history adds some texture. The June 18 Q4 print — the most recent entry — produced only a 0.3% next-day move, barely notable. The March 26 result was more consequential: a 4.5% one-day drop, followed by a partial recovery over the following week. The stock has gained around 3.5% over the past month to $210.59, paring the rally from the $213 highs seen mid-week. Peers have been broadly stronger on the week — TXRH added 7.4%, CBRL gained 6.8%, and BLMN rose 7.8%, all outpacing DRI's more modest 0.7% weekly gain.
The key question heading into June 25 is whether LongHorn momentum and Olive Garden comp trends can keep EPS estimate upgrades running, or whether Evercore's caution about the elevated multiple proves better-timed than the call-buyers' optimism.
See the live data behind this article on ORTEX.
Open DRI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
